Finally, we provided in vitro and in vivo evidence that the growth of cells and tumors that lack SOCS2-AS1 may be effectively blocked by AURKA inhibition, raising the possibility that SOCS2-AS1 loss in cancer cells may predict an anti-AURKA benefit. The gene discussed is AURKA; the disease is cancer.